Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685 91. 136. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventric- ular dysfunction, or both. N Engl J Med 2003;349:1893 906. 137. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385 90. 138. Vantrimpont P, Rouleau JL, Wun CC, et al., SAVE Investigators. Additive bene cial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997;29:229 36. 139. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33: 916 23. 140. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47: 2326 31. 141. A lalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a compar- ative meta-analysis of randomised controlled trials. Heart 2007;93: 914 21. 142. Ho JE, Waters DD, Kean A, et al. Relation of improvement in estimated glomerular ltration rate with atorvastatin to reductions in hospitaliza- tions for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol 2012;109:1761 6. 143. Strandberg TE, Holme I, Faergeman O, et al. 